Cannabis nutrition company focuses on education

Cannabis nutrition company focuses on education

A particular focus is put on the emerging research about cannabis and its benefits for the human body.

Pharma spending on CME rose in 2016

Pharma spending on CME rose in 2016

It's the third year of consecutive growth for spending on accredited CME, according to the Accreditation Council for Continuing Medical Education.

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.

Outcome Health raises $500 million in financing round

Outcome Health raises $500 million in financing round

The deal highlights ongoing interest in the influential point-of-care market.

2017 Pharma Report: All the data in one place

2017 Pharma Report: All the data in one place

Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.

Pricing pressure is the new new normal for drugmakers

Pricing pressure is the new new normal for drugmakers

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.

Otsuka, Proteus refile their sensor-enabled drug

Otsuka, Proteus refile their sensor-enabled drug

The chip-in-a-pill combines antipsychotic Abilify with an ingestible sensor made by Proteus.

Back at Dendreon, Caggiano takes on Provenge's comeback

Back at Dendreon, Caggiano takes on Provenge's comeback

Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.

Five things for pharma marketers to know: Monday, May 8, 2017

Five things for pharma marketers to know: Monday, May 8, 2017

Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions

Value-based care requires innovators to challenge the status quo

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

4 reasons why patients don't fill their prescriptions

4 reasons why patients don't fill their prescriptions

Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.

Drugmakers battle for slice of Humira's billions

Drugmakers battle for slice of Humira's billions

Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.

Top 25 autoimmune brands in 2016, based on U.S. sales

Top 25 autoimmune brands in 2016, based on U.S. sales

AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.

Study: Medical-marijuana laws lower prescription drug usage

Study: Medical-marijuana laws lower prescription drug usage

The research found a reduction in utilization of medications used to treat depression, nausea, and psychosis when looking at data for Medicaid beneficiaries.

5 of healthcare's hardest nuts to crack

5 of healthcare's hardest nuts to crack

How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?

How pharma marketers are using behavioral science

How pharma marketers are using behavioral science

A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.

Pro Ad Report: All the data on medical journal spending in 2016

Pro Ad Report: All the data on medical journal spending in 2016

The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.

Top 25 respiratory brands, by sales

Top 25 respiratory brands, by sales

While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

Five things for pharma marketers to know: Wednesday, March 8, 2017

Five things for pharma marketers to know: Wednesday, March 8, 2017

Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs

Some CME experts remain skeptical when it comes to social media

Some CME experts remain skeptical when it comes to social media

There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.

Doctors seek more transparency from drugmakers: ePharma panel

Doctors seek more transparency from drugmakers: ePharma panel

Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.

Drugmakers again boost DTC spending, to $5.6 billion in 2016

Drugmakers again boost DTC spending, to $5.6 billion in 2016

Pfizer and Bristol-Myers Squibb were the top spenders last year.

2017 Healthcare Marketers Trend Report: All the data in one place

2017 Healthcare Marketers Trend Report: All the data in one place

The data stems from the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.

Why Philips' Erik Hollander turned to reinvention

Why Philips' Erik Hollander turned to reinvention

He describes his current charge as "transforming a more creative occupation into a science."

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant added 250 primary care sales reps to promote its Salix portfolio.

Five things for pharma marketers to know: Tuesday, February 28, 2017

Five things for pharma marketers to know: Tuesday, February 28, 2017

J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking

Top 25 rare disease brands, by sales

Top 25 rare disease brands, by sales

Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.

Orphan drugs face criticism on prices — and from patients

Orphan drugs face criticism on prices — and from patients

When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.

Allergan to boost investment in DTC for Kybella

Allergan to boost investment in DTC for Kybella

Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.

GSK prepares for Advair competition

GSK prepares for Advair competition

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.

Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy

Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy

The drugmaker is planning a commercial boost for its HIV-prevention drug.

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Sales of Keytruda miss analysts' mark

Sales of Keytruda miss analysts' mark

Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.

WPP wins Walgreens account, to create 'Team WBA'

WPP wins Walgreens account, to create 'Team WBA'

WPP will create "Team WBA," a bespoke team that would work on traditional and digital advertising, media, and PR.

Five things for pharma marketers to know: Monday, January 30, 2017

Five things for pharma marketers to know: Monday, January 30, 2017

Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit

Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Infographic: How Trump will affect healthcare marketing budgets

Infographic: How Trump will affect healthcare marketing budgets

A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.

Survey: 26% of brand execs say Trump will affect 2017 marketing budgets

Survey: 26% of brand execs say Trump will affect 2017 marketing budgets

A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.

Top 25 metabolic brands, by sales, 2015-2016

Top 25 metabolic brands, by sales, 2015-2016

Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.

When it comes to diabetes, will marketers break with tradition?

When it comes to diabetes, will marketers break with tradition?

That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

"In Australia, we are the healthcare industry," he says.

Top 25 cardiovascular brands, 2015-2016

Top 25 cardiovascular brands, 2015-2016

The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.

When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?

MM&M's top stories of 2016

MM&M's top stories of 2016

Find out what stories generated the most interest among our readers.

Five things for pharma marketers to know: Wednesday, December 7, 2016

Five things for pharma marketers to know: Wednesday, December 7, 2016

Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.

The doctor-patient dialogue: As productive as it's ever been or broken?

The doctor-patient dialogue: As productive as it's ever been or broken?

More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.

Infographic: what information doctors need from pharma

Infographic: what information doctors need from pharma

How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information

With more marketing spend behind it, Eliquis gains on market leader Xarelto

With more marketing spend behind it, Eliquis gains on market leader Xarelto

BMS and Pfizer outspent Johnson & Johnson two-to-one in advertising for their oral anticoagulant last year.

Insurers seek to challenge millennial 'invincibility'

Insurers seek to challenge millennial 'invincibility'

Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.

Top 25 neurology products, based on 2016 sales forecasts

Top 25 neurology products, based on 2016 sales forecasts

MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.

Pro ad report: All the data on journal spending in 1H 2016

Pro ad report: All the data on journal spending in 1H 2016

Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.

Merck outspends Bristol-Myers Squibb on journal ads for Keytruda

Merck outspends Bristol-Myers Squibb on journal ads for Keytruda

Merck doled out more than $2 million to target doctors in the first half of the year, while BMS spent only $863,000.

EvolveMKD picks up Merz's Mederma account

EvolveMKD picks up Merz's Mederma account

The firm will handle communications for scar treatment Mederma and is already managing the product launch of cellulite-treatment product Cellfina, the 10-year anniversary of injectable Radiesse, and introducing a product line.

Five things for pharma marketers to know: Friday, October 7, 2016

Five things for pharma marketers to know: Friday, October 7, 2016

73% of derms take industry money; Area 23, Klick Health, and UnitedHealthcare win big at the MM&M Awards; IPG launches healthcare media agency

Five things for pharma marketers to know: Wednesday, October 5, 2016

Five things for pharma marketers to know: Wednesday, October 5, 2016

The FDA to require black-box warnings for hep.-C drugs; AstraZeneca's Brilinta fails to meet study goals; ICER says PD-1s are too pricey

7 ways Viagra changed how drugs are marketed

7 ways Viagra changed how drugs are marketed

The inside story on a campaign for the ages, as told by the individuals who worked on it.

The provider gift ban: The day the tchotchkes died

The provider gift ban: The day the tchotchkes died

For some people in the industry ecosystem, the appeal of promo knickknacks endures.

How five therapies changed the course of pharma history

How five therapies changed the course of pharma history

And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.

Five things for pharma marketers to know: Wednesday, September 28, 2016

Five things for pharma marketers to know: Wednesday, September 28, 2016

Patient advocacy groups stay silent in drug-pricing debate; Opdivo to be tested in combination with Nektar drug; 25% of FDA employees now work for industry

The FDA, Astellas, and Accenture use innovation competitions to help address business challenges

The FDA, Astellas, and Accenture use innovation competitions to help address business challenges

The organizations are using innovation competitions to challenge internal and external audiences with coming up with new ideas.

The FDA approves Amgen's biosimilar version of Humira

The FDA approves Amgen's biosimilar version of Humira

Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.

Five things for pharma marketers to know: Wednesday, September 21, 2016

Five things for pharma marketers to know: Wednesday, September 21, 2016

Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight

Pharma's access to docs declines as nonpersonal promotion increases

Pharma's access to docs declines as nonpersonal promotion increases

Sales reps are now more likely to engage with physicians through nonpersonal promotion than in-person visits with doctors at their offices, a ZS report finds.

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

One analyst envisions how a first-line approval could set up Keytruda for success in other settings.

CEO: Allergan will limit price increases for branded drugs

CEO: Allergan will limit price increases for branded drugs

CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.

Mylan's branded ad spending on the EpiPen rose 357% — to $43 million in 2015 — over five years

Mylan's branded ad spending on the EpiPen rose 357% — to $43 million in 2015 — over five years

In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.

Infographic: How physicians share online info with patients and other docs

Infographic: How physicians share online info with patients and other docs

The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.

The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Top 25 women's health products, ranked by 2016 forecasts

Top 25 women's health products, ranked by 2016 forecasts

Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.

Reimbursement rather than Brexit more likely to impact how drugmakers order global launches

Reimbursement rather than Brexit more likely to impact how drugmakers order global launches

The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.'s vote to exit the E.U.

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Only one new osteoporosis drug has been approved over the last six years.

Drugmakers condemn ICER-funded study on PCSK9s

Drugmakers condemn ICER-funded study on PCSK9s

A new study published in JAMA said PCSK9 inhibitors are not worth their high prices.

Valeant salesforce stabilizes as Xifaxan rebounds

Valeant salesforce stabilizes as Xifaxan rebounds

Valeant had deployed roughly 100 additional sales reps this year to promote Xifaxan's indication in hepatic encephalopathy.

Event company acquires AstraZeneca's medical meetings app

Event company acquires AstraZeneca's medical meetings app

The event technology platform plans to integrate a conference note-taking app developed by AstraZeneca and DigitasLBi.

Five things for pharma marketers to know: Thursday, July 28, 2016

Five things for pharma marketers to know: Thursday, July 28, 2016

Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin

Infographic: Type 2 diabetes, a country-by-country snapshot

Infographic: Type 2 diabetes, a country-by-country snapshot

Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.

Five things for pharma marketers to know: Tuesday, July 26, 2016

Five things for pharma marketers to know: Tuesday, July 26, 2016

Sales of Gilead's HCV drugs fall; the DNC policy platform criticized price gouging; Janssen partners with Bristol-Myers Squibb on Opdivo combo drug

Five things for pharma marketers to know: Monday, July 25, 2016

Five things for pharma marketers to know: Monday, July 25, 2016

Darzalex may interfere with blood testing; Kaine scrutinized for ties to pharma; medical societies are in support of bill exempting CME reporting

As immuno-oncology therapies evolve, so will the marketing

As immuno-oncology therapies evolve, so will the marketing

Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.

Five things for pharma marketers to know: Thursday, July 21, 2016

Five things for pharma marketers to know: Thursday, July 21, 2016

The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers

Novartis ups marketing investment in Entresto, by $200 million

Novartis ups marketing investment in Entresto, by $200 million

One oft-cited challenge to Entresto's adoption has been prior authorization requirements.

Five things for pharma marketers to know: Tuesday, July 19, 2016

Five things for pharma marketers to know: Tuesday, July 19, 2016

The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants

Five things for pharma marketers to know: Thursday, July 7, 2016

Five things for pharma marketers to know: Thursday, July 7, 2016

EpiPen price hikes led to syringe use; states with medical marijuana laws have drops in drug spending; Pfizer and Merck KGaA start ovarian cancer trial

Five things for pharma marketers to know: Friday, July 1, 2015

Five things for pharma marketers to know: Friday, July 1, 2015

Drugmakers doled out $452 million to UK healthcare providers; GSK, Pfizer see big market in vaccines for expectant mothers; Shire ADHD drug meets endpoint

Five things for pharma marketers to know: Monday, June 20, 2016

Five things for pharma marketers to know: Monday, June 20, 2016

Novartis plans to launch five biosimilars; Making A Murderer directors will create project based on J&J investigation; Biogen plans to close or sell manufacturing plant

Five things for pharma marketers to know: Wednesday, June 15, 2016

Five things for pharma marketers to know: Wednesday, June 15, 2016

Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway

Boehringer Ingelheim launches gamified support program

Boehringer Ingelheim launches gamified support program

BI launched a new gamified patient support program aimed at improving adherence to its COPD medication.

Valeant CEO blames salesforce turnover for disappointing Xifaxan sales

Valeant CEO blames salesforce turnover for disappointing Xifaxan sales

Turnover in the company's salesforce for its flagship brand have led to disappointing sales, according to Valeant brass.

Five things for pharma marketers to know: Tuesday, June 7, 2016

Five things for pharma marketers to know: Tuesday, June 7, 2016

Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database